15.06.2020 06:02:23
|
Novo : Once-weekly Insulin Icodec Shows Comparable Efficacy To Once-daily Insulin Glargine U100
(RTTNews) - Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analogue. In the trial, adults with type 2 diabetes randomised to once-weekly insulin icodec achieved similar blood sugar control and a similar safety profile compared with adults with type 2 diabetes randomised to once-daily insulin glargine U100.
The 26-week, randomised, double-blind, double-dummy, treat-to-target phase 2 clinical trial involved 247 insulin-naïve adults with type 2 diabetes inadequately controlled with metformin with or without a DPP-4i.
The primary endpoint showed that the change from baseline to week 26 in blood sugar control (HbA1c) was similar in participants receiving once-weekly insulin icodec compared to once-daily insulin glargine U100.
The company expects to initiate the phase 3 clinical development programme for once-weekly insulin icodec later in 2020.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novo Nordisk (spons. ADRs)mehr Nachrichten
Analysen zu Novo Nordisk (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
Novo Nordisk (spons. ADRs) | 76,20 | 2,14% |
|